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Plasmacytoid dendritic cells (pDCs) regulate innate and adaptive immunity. Neurotro­
phins and their receptors control the function of neuronal tissue. In addition, they 
have been demonstrated to be part of the immune response but little is known about 
the effector immune cells involved. We report, for the first time, the expression and 
immune­regulatory function of the low affinity neurotrophin receptor p75 neurotrophin 
receptor (p75NTR) by the antigen­presenting pDCs, mediated by toll­like receptor (TLR) 
9 activation and differential phosphorylation of interferon regulatory factor 3 and 7. The 
modulation of p75NTR on pDCs significantly influences disease progression of asthma 
in an ovalbumin­induced mouse model mediated by the TLR9 signaling pathway. 
p75NTR activation of pDCs from patients with asthma increased allergen­specific T cell 
proliferation and cytokine secretion in nerve growth factor concentration­dependent 
manner. Further, p75NTR activation of pDCs delayed the onset of autoimmune diabetes 
in RIP­CD80GP mice and aggravated graft­versus­host disease in a xenotransplantation 
model. Thus, p75NTR signaling on pDCs constitutes a new and critical mechanism con­
necting neurotrophin signaling and immune response regulation with great therapeutic 
potential for a variety of immune disorders.
Keywords: plasmacytoid dendritic cells, p75 neurotrophin receptor, neurotrophin, Tlr9, autoimmune diabetes, 
graft-versus-host disease, allergic asthma
inTrODUcTiOn
Plasmacytoid dendritic cells (pDCs) are a subset of dendritic cells that act at the interface of innate 
and adaptive immune responses. As antigen-presenting cells, pDCs modulate the differentiation 
and activity of T cell subsets, including TH1, TH2, TH17, and regulatory T cells. They are primar-
ily linked to the host defense against pathogens and to pathogen adverse effects, particularly 
2Bandoła et al. p75NTR and pDCs
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 981
virus-induced interferon (IFN) α production (1, 2). pDCs are 
critically involved in the clearance of viral infections and are 
implicated in the pathophysiology of immune disorders (3, 4). 
In allergic diseases, IFNα secretion from pDCs is blocked by IgE 
disinhibiting TH2 and TH17 inflammatory reactions (5). Further, 
pDCs may prevent generation of effector T  cells (4). A more 
complex field is evolving with regard to pDCs contribution in 
the pathology of type 1 diabetes (T1D): IFNα secretion by pDCs 
upon pancreotropic virus infection may be protective by reduc-
ing viral loads, whereas IFNα secretion may as well activate 
autoreactive T  cells (6). In graft-versus-host disease (GvHD), 
pDCs presenting alloantigen may prime alloreactive T  cells 
triggering GvHD (7). After allogeneic stem cell transplantation, 
diminished peripheral blood pDCs counts were associated with 
poorer odds of survival (8). Therefore, regulation of pDCs func-
tions is an essential element in immune homeostasis.
The family of neuronal growth factors—the neurotrophins 
nerve growth factor (NGF), brain-derived neurotrophic fac-
tor (BDNF), neurotrophin 3, and neurotrophin 4/5—mediate 
the development, survival, and function of neuronal tissues. 
Neurotrophin signaling is mediated by tropomyosin-related 
kinase receptors (Trk) and the low affinity p75 neurotrophin 
receptor (p75NTR) (9). p75NTR belongs to the tumor necrosis 
factor receptor superfamily and consists of an extracellular, a 
transmembrane, and an intracellular domain. The extracellular 
domain contains four cysteine rich repeats that are crucial for 
NGF-p75NTR interaction (10). Transgenic disruption of exon 
III encoding cysteine rich repeat 2–4 destroyed the neurotrophin 
binding site in mice but produced viable animals (Ex3 mutant) 
without detectable expression of full length p75NTR (11). 
Interestingly, both wild-type and Ex3-mutant mice still express 
an alternative splice variant of p75NTR lacking exon III and 
thus a functional extracellular binding site for neurotrophins 
(12). Beside neuronal tissue, the expression of Trk receptors and 
p75NTR was detected in a variety of immune cells. B and T lym-
phocytes, macrophages, basophils, and mast cells express TrkA, 
and p75NTR expression was shown in B  cells and mast cells 
[as reviewed in Ref. (13–15)]. The NGF-promoted effects com-
prise chemoattraction, activation and differentiation of neutro-
phils, TH2 lymphocyte proliferation, and B cell survival, among 
others (16). Furthermore, the neurotrophins and p75NTR 
have been demonstrated to play a pivotal role in the etiology 
of immune disorders. Bronchoalveolar lavage samples from 
patients with asthma contain high concentrations of neurotro-
phins, and mice with inactivated p75NTR fail to develop an oval-
bumin (OVA)-induced asthma (17, 18). p75NTR-deficient mice 
with experimental autoimmune encephalitis exhibit enhanced 
inflammatory responses (19). Endogenous levels of NGF have 
been shown to be altered in human and experimental diabetes, 
while p75NTR was shown to regulate glucose homeostasis and 
insulin sensitivity in diabetes (20–22). Thus, it has been postu-
lated that neurotrophins and p75NTR transmit signals directly 
to the immune cells.
In the present study, we report the discovery of a new role 
for p75NTR signaling during pDC-mediated immune responses 
applying models of an allergic asthma, an autoimmune diabetes 
type I (T1D) and a GvHD.
MaTerials anD MeThODs
animals
The p75NTR (Ex3)-mutant strain (B6.129S4-Ngfrtm1Jae/J) 
and the NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) 
were purchased from The Jackson Laboratory (11, 23). The 
OT-I (C57BL/6-Tg (TcraTcrb)1100Mjb/Crl) and the OT-II 
(C57BL/6-Tg (TcraTcrb)425Cbn/Crl) strain were purchased from 
Charles River (24, 25). Heterozygous RIP-CD80GP mice were 
generated by cross-breeding RIP-CD80 with RIP-lymphocytic 
choriomeningitis virus glycoprotein (LCMV-GP) mice as previ-
ously described (26). All mice were bred under pathogen-free 
conditions in the animal facility of the Technische Universitaet 
Dresden. Male and female mice 10–12 weeks of age were used for 
the experiments. All animal experiments were carried out in strict 
accordance with the German Animal Welfare Act. The protocol 
was approved by the Committee on Ethics of the Landesdirektion 
Dresden, Germany (Permit Number: 24-9168.11-1/2010-34, 
24-9168.11-1/2013-32).
isolation of human pDcs and T cells
Plasmacytoid dendritic cells were isolated after donors granted 
informed consent with approval of the local ethics committee 
(EK 155052009). Cells were purified using magnetic cell separa-
tion (MACS, Miltenyi Biotec) according to the manufacturer’s 
instructions. For in  vitro assays, pDCs and CD4+ T  cells were 
purified using BDCA-4 MicroBeads and a CD4+ T cell Isolation 
Kit II, respectively. For transplantation, pDCs and T cells were 
purified using a pDC Isolation Kit II and a Pan T cell Isolation 
Kit, respectively. The purities of pDCs (BDCA-2+, BDCA-4+) 
and T  cells (CD3+) were greater than 95% as assessed by flow 
cytometric analysis.
stimulation of human pDcs In Vitro
Isolated pDCs (5 × 104 cells/96-well cavity) were seeded in 200 µl 
of RPMI 1640 medium (Thermo Fisher Scientific) supplemented 
with 100  IU  ml−1 penicillin, 100  µg  ml−1 streptomycin, 2  mM 
l-glutamine, 10% (vol/vol) human serum and recombinant 
human  (rh) IL-3 [10  ng  ml−1; R&D Systems]. To determine 
the levels of secreted IFNα, pDCs were cultured for 12–14 h in 
the presence of ODN 2216 (CpG A; 0.26  µM; Thermo Fisher 
Scientific). To block p75NTR activity, the inhibitory peptide 
TAT-Pep5 (100  nM, Merck) was added. Recombinant human 
β-NGF (R&D Systems) was added at the indicated concentra-
tions. The IFNα levels in supernatants were determined using 
an ELISA (eBioscience). To determine the levels of secreted 
IL-6, pDCs were stimulated with an antibody specific to human 
FcεRlα (250 ng ml−1; eBioscience) alone or in the presence of the 
TAT-Pep5 inhibitor. Recombinant human β-NGF was added at 
the indicated concentrations. After 14  h, the supernatant was 
collected to measure IL-6 levels using an ELISA (eBioscience).
autologous coculture of human pDcs  
and cD4+ T cells In Vitro
CD4+ T cells and pDCs were isolated from an individual with an 
untreated, well-defined allergy. CD4+ T cells were stained with 
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CFSE (1 µM; Thermo Fischer Scientific) for 8 min at 37°C followed 
by the addition of 1 ml warmed FCS. The cells were washed twice 
and counted directly before starting the coculture. Purified pDCs 
and CFSE-labeled T cells were cocultured (ratio 1:6) in a 96-well 
U-bottom plate at 37°C and in an atmosphere containing 5% (vol/
vol) CO2. Each well contained 200 µl of RPMI 1640 medium sup-
plemented with 100 IU ml−1 penicillin, 100 µg ml−1 streptomycin, 
2  mM l-glutamine, 10% (vol/vol) human serum, and rh IL-3 
(10 ng ml−1). Recombinant human β-NGF (5 or 25 ng ml−1) was 
added to the designated wells. Respective allergens were added to 
the coculture at 50 SBE U ml−1 (ALK-Abelló Arzneimittel). After 
5 days of coculture, the plate was centrifuged at 270 × g for 5 min, 
and the supernatant was collected. The levels of TH1- and TH2-
specific cytokines were measured using a cytometric bead array 
(CBA) assay (BD Biosciences), and the percentage of proliferating 
CD4+ T cells was determined by quantification of CFSE signal 
intensity using flow cytometry. CD4+ T  cells with lower CFSE 
signals compared to initial CFSE staining signal were assumed as 
proliferating T cells and percentage of proliferating T cells were 
calculated in relation to all T cells (CD3+).
Xenotransplantation gvhD Model
Recipient mice from the NSG strain received sublethal whole 
body irradiation using an Yxlon MaxiShot X-ray irradiator 
(Yxlon; 100  cGy), 20  h prior to human cell transplantation. 
Human pan T cells and human pDCs from five healthy donors 
were isolated as described above. Autologous pan T cells (2 × 106/
setup and donor) and pDCs (2 × 105/setup and donor; ratio 10:1) 
were cultured together overnight in 200 µl RPMI 1640 complete 
medium containing rh IL-3 (10 ng ml−1) and human AB serum 
in the absence or presence of CpG A (0.26 µM) and rh β-NGF 
(25 ng ml−1). Next day, cell suspensions in 1× PBS (150 µl) were 
injected into the retro-orbital venous plexus using 25-gauge 
needles. For the first 3 weeks after transplantation, water was sup-
plemented with neomycin (1.17 g l−1, Sigma-Aldrich). Mice were 
sacrificed when deterioration of health as recognized by weight 
loss (≥20% of starting weight), reduced activity, reduced pair 
grooming, inability to intake food, neurological malfunction, or 
self-mutilation appeared. Primary endpoint was overall survival 
with a maximal follow-up of 12 weeks after cell transplantation. 
Peripheral blood of the recipients was obtained every 1–2 weeks 
by venipuncture of the retro-orbital venous plexus using hep-
arinized microcapillaries. Red blood cell lysis was performed 
using ACK lysis buffer (Thermo Fisher Scientific) according to 
manufacturer’s instructions. Distribution of human and murine 
cells in peripheral blood was analyzed by flow cytometry.
isolation of Murine splenocytes
In order to isolate murine splenocytes, the spleen was dissected 
and a 70-µm cell strainer was used to generate single cell suspen-
sion from whole spleen. Cells were centrifuged for 8 min at 300 g 
at 4°C. Erythrocytes were removed using ACK lysis buffer accord-
ing to manufacturer’s instructions. After the washing step, the 
cells were suspended in RPMI 1640 medium supplemented with 
10% (vol/vol) FCS, 1 mM sodium pyruvate, 2 mM l-glutamine, 
100 IU ml−1 penicillin, 100 µg ml−1 streptomycin, 10 mM HEPES 
buffer, and 0.1 mM β-mercaptoethanol.
generation of Mouse pDcs
Bone marrow (BM)-derived pDCs were generated in  vitro as 
described previously (27). Briefly, BM  cells were isolated from 
mice by flushing the femur and tibia. Erythrocytes were lysed 
using ACK lysis buffer according to manufacturer’s instructions. 
The remaining cells were washed and cultured at a density of 
2 ×  106  cells  ml−1 in RPMI 1640 medium supplemented with 
10% (vol/vol) FCS, 1 mM sodium pyruvate, 2 mM l-glutamine, 
100 IU ml−1 penicillin, 100 µg ml−1 streptomycin, 10 mM HEPES 
buffer, and 0.1 mM β-mercaptoethanol. To differentiate BM cells 
into pDCs, rh Flt3-L (100  ng  ml−1; R&D Systems) was added 
to the cells. After 8  days, pDCs were enriched by removing 
the CD11b+ cells from the non-adherent cells, using CD11b 
MicroBeads (Miltenyi Biotec) according to manufacturer’s 
instructions. Dead cells were excluded using a dead cell removal 
Kit (Miltenyi Biotec). The purity of BM-derived pDCs (B220+, 
SiglecH+, mPDCA1+, CD11b−) was greater than 98% according 
to flow cytometric analysis.
stimulation of Mouse pDcs In Vitro
For all in vitro stimulation assays, 2 × 105 cells were cultured at 
200 µl per 96-well of RPMI 1640 complete medium in the pres-
ence of either ODN1585 (CpG A, 1 µM; Invivogen), ODN1826 
(CpG B, 1 µM; Invivogen), lipopolysaccharide (LPS, 1 µg ml−1; 
Sigma-Aldrich), low endotoxin ovalbumin (OVA LE; 1 µg ml−1; 
Invivogen), or grade V ovalbumin (OVA V, 1  µg  ml−1; Sigma-
Aldrich). Control cells were left untreated. If not stated otherwise, 
recombinant murine (rm) β-NGF (100 ng ml−1; R&D Systems) 
was used according to previous studies of a mouse model of OVA-
mediated allergic asthma (28). The production of mouse IFNα 
was measured 24  h after set-up using an ELISA (eBioscience). 
Murine IL-6 and TNFα levels were assessed using a CBA (BD 
Biosciences). The remaining cells were used for flow cytometric 
analysis.
coculture of Mouse pDcs and T cells
Before coculture, purified BM-derived wild-type (WT) or Ex3 
pDCs were incubated overnight with OVA V (100 µg ml−1) in the 
absence or presence of rm β-NGF (100 ng ml−1) and then washed 
and suspended in RPMI 1640 complete medium. Control cells 
were incubated without OVA V. Untreated CD4+ T and CD8+ 
T cells from the OT-II and OT-I strains, respectively, were isolated 
from mouse splenocytes using MACS Microbeads (CD4+ T cell 
Isolation Kit II, CD8α+ T cell Isolation Kit II, Miltenyi Biotec). 
CD4+ and CD8+ T cells were stained with CFSE (1 µM) according 
to manufacturer’s instructions. CFSE-labeled T cells and pDCs 
were cocultured (ratio 10:1) in 200  µl of RPMI 1640 complete 
medium in a 96-well culture plate at 37°C for 4 days. The culture 
plates were then centrifuged at 400 × g for 4 min at 4°C. Cytokine 
levels were measured using a CBA (BD Bioscience), and T cell 
proliferation was determined by flow cytometric analysis of CFSE 
signal intensity.
induction of autoimmune Diabetes in Mice
Bone marrow-derived WT pDCs were stimulated for 2  h with 
CpG B (1  µM) and the lymphocytic choriomeningitis virus 
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(LCMV) gp33-41 peptide (10  µM; Eurogentec) in the absence 
or presence of rm β-NGF (100 ng ml−1) in RPMI 1640 complete 
medium at 0.5 ×  106  cells  ml−1. Cells were washed twice with 
1× PBS. Finally, cell suspension (1.7 × 106 pDCs in 150 µl 1× PBS) 
was injected intravenously into the tail vain of heterozygous RIP-
CD80GP mice. Blood glucose levels were measured twice weekly 
using the Glucometer Elite (Bayer Diagnostics). Mice were sac-
rificed immediately after positive diagnosis of diabetes defined 
by two consecutive blood glucose levels above 250  mg  dl−1. If 
not stated otherwise, mice were followed for 48  days post cell 
transplantation.
induction of OVa-specific allergic  
asthma in Mice
Sensitization to OVA was performed as described by Lambrecht 
et al. with minor modifications (29). To induce allergic asthma, 
pDCs generated in  vitro were first incubated with 100  µg  ml−1 
OVA V in the absence or presence of rm β-NGF (0.1 or 
100 ng ml−1) for the next 24 h. Next, 1 × 106 OVA V-loaded pDCs 
were injected intratracheally into the lungs of anesthetized mice 
using a 24-gauge i.v. cannula (BD Biosciences). Control animals 
received either the same amount of pDCs without OVA V or 
with PBS only. After 10 days, mice were exposed to an OVA V 
aerosol [1% (wt/vol)] for 30  min on three consecutive days to 
induce an allergic reaction. Animals were sacrificed 24 h after the 
last provocation, and the presence of an immune reaction was 
assessed according to the cell composition of the bronchoalveolar 
lavage fluid (BALF), proinflammatory cytokine levels, and lung 
histology.
analysis of BalF
Cells present in BALF were quantified using flow cytometry 
according to a modified method described previously (30). To 
minimize non-specific binding, cells were preincubated with FcR 
blocking reagent (Miltenyi Biotec). Among lymphocytes (FSClow/
SSClow), the CD4+ T  cells were designated as CD3+ CD4+, the 
CD8+ T cells as CD3+ CD8+, B cells as CD3− B220+, and among 
granulocytes (FSClow/SSChigh, Ly6G+) eosinophils were desig-
nated SiglecF+ CD11c− and neutrophils as SiglecF−. Macrophages 
were defined as FSChigh highly autofluorescent CD11c+ F4/80+. 
Cytospins were stained using Pappenheim’s method. Staining 
patterns are as follows: cell nuclei are stained purple to violet, 
plasma lymphocytes are light blue, monocytes/macrophages are 
violet, the granules of eosinophils are red-brown, and neutro-
phils are light violet. ELISA (eBioscience) was used to quantify 
the levels of IL-4, IL-5, and IL-13 according to manufacturer’s 
instructions.
histological analyses
Lungs were perfused with 1× PBS and fixed in 4% (vol/vol) 
formaldehyde. 4-µm sections of paraffin-embedded lungs were 
stained with PAS to quantify inflammation and Goblet cell hyper-
plasia. The number of Goblet cells in stained lung sections was 
determined using a 5-point scoring system as follows: grade 0, 
none detected in the epithelium; grade 1 < 25%; grade 2, 25–50%; 
grade 3, 51–75%; and grade 4 > 75%.
Flow cytometry
Flow cytometric analyses were conducted using an LSR II flow 
cytometer (BD Biosciences). Data were evaluated using FlowJo 
software (Version 7.6.5; Flowjo). All antibodies against human or 
mouse cells were used at appropriate dilutions, as determined by 
previous titration. Doublet discrimination was carried out and 
non-viable cells were excluded by 4,6 diamidino-2-phenylindole 
(DAPI) staining (Sigma-Aldrich). Mouse cells were characterized 
using the antibodies as follows: CD3-V500, CD4-V450, CD11c-
APC Cy7, SiglecF-AF647, Ly6G-FITC, CD11b-V500, B7-1-V450, 
B7-2-PE Cy7, CD62L-FITC (BD Biosciences); mPDCA1-
APC, B220-PE (Miltenyi Biotec); CD8-PE Cy7, F4/80-PerCP, 
SiglecH-PE, TLR4-AF488, TLR9-FITC, MHC-I-FITC, MHC-
II-V450, PD-L1-PerCP, ICOS-L-PE, OX40L-APC (eBioscience); 
TLR7-PE (Abcam); p75NTR-AF488 (Advanced Targeting 
Systems), CD45-Pacific Blue (Biolegend), and panTrk-FITC (Cell 
Signaling Technology). Human cells were characterized using 
the antibodies as follows: TrkA-PE (R&D Systems); BDCA-2-
FITC, BDCA-4-PE, p75NTR-APC, p75NTR-FITC, p75NTR-PE 
(Miltenyi Biotec); CD45-V500, CD3-PE, CD4-FITC, CD8-PerCP, 
FcεRIα-FITC, IL-3R-PE Cy7, CD184-PE Cy7, MHC-I-PE Cy7, 
MHC-II-PE, CD80-V450, CD86-PE, CD83-V500, OX40L-V500, 
PD-L1-PE Cy7, CCR7-V450, CCR9-APC (BD Biosciences), 
CD3-APC eFluor780, CD4-APC, CD8-PE Cy7, CD25-PE (eBio-
science), and CD69-PerCP Cy5.5 (BioLegend).
Western Blotting
Whole-cell lysates were prepared from BM-differentiated pDCs. 
For signaling pathway analyses, the cells were first cultured for 
5 h in the absence or presence of rm β-NGF (100 ng ml−1) and 
treated for 15  min with CpG A or CpG B (1  µM) each. Then, 
the cells were immediately collected for protein isolation using 
complete RIPA buffer containing MiniComplete Protease inhibi-
tor cocktail and PhosSTOP Phosphatase inhibitor cocktail (Roche 
Diagnostics). The reduced and denatured protein samples (10 µg) 
were loaded onto a NuPAGE 4–12% Bis-Tris gel (Thermo Fisher 
Scientific), electrophoresed, and transferred electrophoretically 
to a nitrocellulose membrane. Immunodetection was conducted 
using the primary antibody specific to following mouse proteins 
generated in rabbit: p75NTR (D4B3), TrkA, MyD88, Phospho-
IRF3, Phospho-IRF7, Phospho-IKKα/β, Phospho-c-Jun (Ser63) II 
(Cell Signaling Technology); TRAF6 (Thermo Fisher Scientific); 
GAPDH (GeneTex). The antibodies were diluted 1:1,000, 
except for the GAPDH antibody (which was diluted 1:10,000). 
Incubation with primary antibody was followed by incubation 
with HRP-conjugated secondary anti-rabbit antibody (GE 
Healthcare) before development using Lumi-Light Plus western 
blot detection system (Roche Diagnostics).
statistical analyses
Unless stated otherwise, data generated from in  vivo experi-
ments were analyzed with one- or two-way ANOVA models. 
In case of comparing mean values of only two groups, Welch’s 
t-test was used. Where necessary, a logarithmic (log) transfor-
mation (natural logarithm, ln, base e) was used to stabilize the 
variance in the different groups. Occurrence of autoimmune 
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diabetes was analyzed with a standard log-rank test comparing 
two groups. Survival time and human T  cell distribution in 
the GvHD xenotransplantation context was described with a 
Cox proportional hazards regression model. For OVA-induced 
asthma model, the ordinal Goblet cell scores on lung sections 
were analyzed via a proportional odds model (31). The OVA-
uptake measurements over time were analyzed with a repeated-
measure ANOVA. Log-scale data from experiments using 
human materials to assess the influence of NGF and p75NTR 
expression level on the secretion of IFNα and IL-6, and the 
proliferation of T cells were evaluated using mixed effect models 
to accommodate for the human donor effect (32). For human 
cytokine data an ordinary two-way ANOVA was performed, as 
the number of donors was too small to be modeled in the context 
of mixed effect models. Post hoc pairwise comparisons in the 
analyses were done either with Tukey’s honest significance test 
based on a multivariate t-distribution for all-pair comparisons 
or with Dunnett’s test for multiple comparisons against a control. 
The number of experimental and technical replicates is shown 
in the figure legends. p-Values of less than 0.05 were considered 
statistically significant. The statistical analyses were done with 
GraphPad Prism (Version 5.04; GraphPad Software) and R 
(Version 3.1.2) (33).
resUlTs
p75nTr Modulates the innate immune 
response of Murine pDcs
Harvesting splenocytes from WT mice for flow cytometric analy-
ses, we detected a cell population that expressed p75NTR without 
expressing high affinity neurotrophin Trk receptors (Figure 1A). 
Analyzing the surface marker expression profile of this p75NTR 
positive cell population in more detail we identified them as 
pDCs (Figure S1A in Supplementary Material).
To assess the role of p75NTR in function of murine pDCs, 
we applied the Ex3 mutant mouse strain. In this strain, a cassette 
is introduced in the third exon of the gene encoding p75NTR 
suppressing the expression of functional p75NTR (11). Except 
for their difference in p75NTR cell-surface expression, primary 
pDCs from spleen of WT and Ex3 mice exhibited no differ-
ences in the levels of their cell-surface markers and showed no 
expression of any of the high affinity neurotrophin receptors 
(Figure  1A; Figure S1A in Supplementary Material). Further, 
BM-derived murine pDCs did not exhibit any difference in cell-
surface marker expression compared with that of primary pDCs 
(Figure 1A; Figure S1A in Supplementary Material).
Regarding the pDC function in innate immune response, 
we determined the expression of toll-like receptors (TLR) 4, 
7, and 9 of receptor-specific stimulated pDCs (Figure S1B in 
Supplementary Material). TLR4, which is typically expressed on 
conventional dendritic cells, was not expressed by WT or Ex3 
pDCs. Only a small subset of WT and Ex3 pDCs expressed TLR7 
increased further by exposing cells to type A (CpG A) or type B 
(CpG B) CpG oligodeoxynucleotides. Similarly, administration 
of CpG A or CpG B markedly increased the percentage of both 
WT and Ex3 pDCs that expressed TLR9. Furthermore, OVA 
with grade-V (OVA V) purity and LPS substantially increased 
the levels of TLR7 and TLR9.
We next tested the influence of NGF on the secretion of 
cytokines by WT and Ex3 pDCs stimulated with CpG A or CpG 
B. When compared with Ex3 pDCs, CpG A-stimulated WT 
pDCs secreted significantly higher levels of IFNα (p =  0.003; 
Figure  1B). Concomitant addition of NGF attenuated IFNα 
secretion by WT pDCs in a significant, concentration-dependent 
manner (100 ng ml−1 NGF: p = 0.0003). NGF had no significant 
effect on mean IFNα levels of Ex3 pDCs. NGF alone did not 
induce a secretion of IFNα by WT or Ex3 pDCs (Figure S1C 
in Supplementary Material). An increased amount of the 
proinflammatory cytokine IL-6 was produced by pDCs treated 
with CpG B. In the presence of NGF (100 ng ml−1), WT pDCs 
secreted significantly higher levels of IL-6 whereas Ex3 pDCs 
did not (p <  0.0001; Figure 1B). WT pDCs treated with CpG 
A expressed significantly reduced levels of TLR9 in response to 
NGF (100 ng ml−1 NGF: p = 0.0011), in a dose-dependent man-
ner (Figure 1B). Interestingly, Ex3 pDCs expressed significantly 
lower basal levels of TLR9 (p = 0.0046) and significantly lower 
levels of TLR9 when treated with CpG A (p < 0.0001) or CpG B 
(p = 0.018; Figure 1B).
To investigate the mechanisms underlying the observed effects, 
we analyzed pDCs using western blotting analysis (Figure 1C). 
WT and Ex3 pDCs expressed comparable levels of MyD88, 
IRAK4, TRAF6, PI3K, TBK1/NAK, and IKKε kinase, which are 
involved in signaling pathways activated by CpG A and CpG B. 
Interestingly, treatment with CpG A increased the phosphoryla-
tion of IRF3, IRF7, IKKα/β, and c-Jun in WT pDCs as compared 
to Ex3 pDCs (Figure  1C). The total protein concentrations of 
IRF3, IRF7, IKKα/β, and c-Jun were comparable among the 
samples. NGF attenuated CpG A-induced phosphorylation of 
the transcription factors IRF3 and IRF7 in WT pDCs, while CpG 
B-induced phosphorylation of IRF3 and IRF7 was augmented 
by NGF treatment (Figure 1C). NGF did not alter the levels of 
CpG-induced phosphorylation of IRF3 and IRF7 expressed by 
Ex3 pDCs.
In conclusion, p75NTR alters the TLR9 specific IFNα secre-
tion of pDC via an altered activation of the interferon regulatory 
factor (IRF) signaling pathway in NGF-treated pDCs.
p75nTr Modulates the ability of Murine 
pDcs to stimulate T cells
Antigen presentation and stimulation of T  cells are central 
functions of pDCs in adaptive immune response. To study 
the effect of p75NTR on pDC driven antigen presentation, we 
incubated WT and Ex3 pDCs with different OVA formula-
tions (Figure 1D). Treating WT and Ex3 pDCs with OVA V 
significantly increased the surface expression of MHC-II (WT: 
p = 0.0001, Ex3: p = 0.0013) and CD86 (WT: p < 0.0001, Ex3: 
p  <  0.0001), although expression was significantly higher 
for both molecules in WT pDCs. Only WT pDCs expressed 
significantly higher levels of cell-surface ICOS-L in response 
to OVA V treatment (p =  0.0004). The addition of NGF in 
combination with OVA V did not alter the expression of these 
molecules on the surface of WT or Ex3 pDCs. Low endotoxin 
FigUre 1 | Continued
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OVA (OVA LE) had no significant effect on the cell-surface 
expression of molecules required for costimulation and antigen 
presentation.
We next determined the ability of WT and Ex3 pDCs to 
stimulate T  cells. For this purpose, we purified T  cells from 
transgenic OT-I and OT-II mice that express OVA-specific 
FigUre 1 | Continued  
Nerve growth factor (NGF) modulates the innate immune response of murine plasmacytoid dendritic cells (pDCs) in vitro. (a) Expression of p75 
neurotrophin receptor and tropomyosin­related kinase receptors on primary pDCs isolated from spleen and bone marrow (BM)­derived pDCs derived from 
wild­type (WT; black line) mice or Ex3 mutant mice (red line). Unstained controls are displayed in gray. (B) Secretion of IFNα and IL­6 and TLR9 protein 
levels by BM­derived WT or Ex3 pDCs stimulated overnight with CpG A or CpG B in the absence or presence of NGF. (c) Total protein and protein 
phosphorylation levels (P) of toll­like receptor signaling pathway members in BM­derived WT or Ex3 pDCs stimulated overnight with CpG A or CpG B in the 
absence or presence of NGF. Evident differences between WT and Ex3 pDCs are indicated by the red­bordered rectangles. Evident changes in 
phosphorylation upon addition of NGF to WT pDCs are indicated by red arrows. (D) Expression of ICOS­L, MHC­II, and CD86 of BM­derived WT or Ex3 
pDCs stimulated overnight with endotoxin­free OVA (OVA LE) or grade­V OVA (OVA V) in the absence or presence of 100 ng ml−1 NGF. (e) IL­6 and TNFα 
levels, and T cell proliferation of cocultures of primary CD4+ OT­II­derived T cells and BM­derived, OVA V­pulsed WT, or Ex3 pDCs in the absence or 
presence of 100 ng ml−1 NGF. (F) IL­6 and TNFα levels, and T cell proliferation of cocultures of primary CD8+ OT­I­derived T cells and BM­derived, OVA 
V­pulsed WT, or Ex3 pDCs in the absence or presence of 100 ng ml−1 NGF. In panels (a,c), representative images are shown. BM­derived WT­pDCs and 
Ex3 pDCs, respectively, are indicated in panels (B,D–F) as black dots and red squares. In panels (B,D–F), number of independent experiments are 
displayed as single marks in scatter plots with mean values indicated by the short horizontal lines. MFI, mean fluorescence intensity (*p < 0.05, 
***p < 0.005, ****p < 0.0001).
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CD8 or CD4 pairing T cell receptors, respectively. Compared to 
cocultures with OVA V-loaded Ex3 pDCs, cocultures with OVA 
V-loaded WT pDCs contained significantly higher levels of IL-6 
(CD4+ OT-II T cells: p = 0.0039, CD8+ OT-I T cells: p = 0.0001) 
and TNFα (CD4+ OT-II T cells: p = 0.0031, CD8+ OT-I T cells: 
p = 0.0023). The proliferation of CD4+ OT-II (p = 0.0001) and 
CD8+ OT-I (p = 0.051) T cells were increased (Figures 1E,F). In 
cocultures of CD4+ OT-II T cells and OVA V-loaded WT pDCs, 
IL-6 (p =  0.042) and TNFα secretion (p =  0.0071), and T  cell 
proliferation (p = 0.0046) were significantly enhanced in the pres-
ence of NGF. In contrast, IL-6 (p = 0.0001) and TNFα (p = 0.0026) 
production, as well as T  cell proliferation (p  =  0.0029) were 
attenuated by NGF treatment in cocultures of CD8+ OT-I T cells 
and OVA V-loaded WT pDCs. A comparable effect of NGF on 
CD4+ OT-II or CD8+ OT-I cocultures with OVA V-loaded Ex3 
pDCs was not observed.
In conclusion, pDC expressed co-stimulatory and antigen-
presentation surface proteins in a p75NTR dependent manner. 
Upon addition of NGF, pDC stimulated the proliferation and 
activity of antigen-specific CD4+ T cells, whereas CD8+ T cells 
displayed an attenuated behavior.
pDcs expressing p75nTr induce  
OVa-Mediated allergic asthma in Mice
To address the role of p75NTR expression by pDCs in immune 
disorders in vivo, we applied a TH2-prone murine model of OVA-
induced allergic asthma. We sensitized WT and Ex3 mice through 
the intratracheal application of OVA V-pulsed WT or Ex3 pDCs 
and induced an allergic reaction by subsequent exposure to OVA 
aerosol.
Wild-type and Ex3 mice treated with OVA V-loaded WT pDCs 
exhibited typical symptoms of allergic asthma upon exposure to 
the OVA V aerosol. The number of lymphocytes and eosinophils 
(Figures  2A,D) and the levels of the TH2 cytokines IL-4, IL-5, 
and IL-13 (Figure 2B) were increased in BALF. WT and Ex3 mice 
sensitized with OVA V-loaded Ex3 pDCs exhibited significantly 
lower amounts of eosinophils (WT mice: p  =  0.00016, Ex3 
mice: p = 0.018) and lymphocytes (WT mice: p = 0.0098), and 
secreted reduced amounts of the proinflammatory cytokines IL-4 
(WT mice: p = 0.018, Ex3 mice: p = 0.018) and IL-5 (WT mice: 
p = 0.049) in the BALF compared with mice treated with OVA-
loaded WT pDCs (Figures 2A,B,D). Perivascular inflammation 
and Goblet cell hyperplasia in the lung were reduced in mice 
treated with Ex3 pDCs, compared with mice treated with WT 
pDCs (WT mice: p < 0.0001, Ex3 mice: p < 0.0001; Figures 2C,E). 
Interestingly, WT and Ex3 mice differed significantly in the num-
ber of lymphocytes (p = 0.049) and secreted IL-5 (p = 0.020) in 
the BALF of animals instilled with WT pDCs.
In conclusion, the inability of Ex3 mice to develop an allergic 
asthma can be allocated to the missing p75NTR expression on 
pDC. Further, formation of antigen-specific inflammation of lung 
tissue solely depends on transplantation of antigen-presenting 
pDC with native p75NTR expression.
ngF augments pDc-Mediated allergic 
asthma in a p75nTr-Dependent Manner
Based on our observations of a pDC-mediated and p75NTR-
dependent immune response in mice, we determined the effect 
of NGF on WT pDCs in experimentally induced asthma. 
For this purpose, we incubated WT pDCs with OVA V in 
the absence or presence of NGF (0.1 or 100  ng  ml−1) before 
intratracheal instillation into WT mice. When OVA V-uptake 
by WT pDCs occurred in the presence of 100  ng  ml−1 NGF, 
the number of eosinophils (compared to 0  ng  ml−1 NGF: 
p  =  0.026, compared to 0.1  ng  ml−1 NGF: p  =  0.027) was 
significantly increased in the BALF, whereas the percentage 
of macrophages (compared to 0.1  ng  ml−1 NGF: p =  0.037) 
was significantly reduced (Figures  2F,H). Moreover, instil-
lation of OVA V-loaded WT pDCs treated with 100  ng  ml−1 
NGF led to significantly increased levels of IL-4 (compared to 
0.1 ng ml−1 NGF: p = 0.043) in the BALF compared to instil-
lation with pDCs pulsed with OVA V in the absence or pres-
ence of 0.1 ng ml−1 NGF (Figure 2G), whereas no significant 
differences were observed for IL-5 and IL-13. Lung sections 
from mice that received OVA V-loaded and NGF-stimulated 
WT pDCs exhibited increased perivascular inflammation and 
enhanced mucus production (Figure 2I).
In conclusion, ligand-specific activation of p75NTR on pDC 
controls the severity of an antigen-specific allergic asthma in mice 
in a concentration-dependent manner.
FigUre 2 | Continued
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FigUre 3 | Nerve growth factor (NGF) alleviates plasmacytoid dendritic cell (pDC)­mediated autoimmune diabetes in vivo. (a) Glucose levels in peripheral blood of 
heterozygous RIP­CD80GP mice transplanted with murine pDCs. Murine pDCs were stimulated with CpG A and lymphocytic choriomeningitis virus peptide 
gp33–41 in the absence (black dots) or presence (blue dots) of NGF. Dots indicate single measurements. Correlation (continuous line) and confidence interval (95%; 
dashed lines) of both treatments are depicted. (B) Diabetes­free incidence of (a) is shown. Diabetes defined by two consecutive blood glucose levels above 
250 mg dl−1. In panels (a,B) data of three independent experiments with two to five animals per group are shown.
FigUre 2 | Continued  
Stimulation of p75 neurotrophin receptor­expressing plasmacytoid dendritic cells (pDCs) with nerve growth factor (NGF) aggravates allergic responses in mice.  
(a) Cellular composition of bronchoalveolar lavage fluid (BALF) harvested from wild­type (WT) or Ex3 mice with ovalbumin (OVA)­induced allergic asthma instilled 
with WT pDCs, Ex3 pDCs, or no cells. (B) Levels of IL­4, IL­5, and IL­13 in BALF described in panel (a). (c) Quantification of Goblet cell hyperplasia using a 5­point 
scoring system as described in Section “Materials and Methods.” Twenty­three bronchi from five recipient mice of each treatment were analyzed. (D) Pappenheim’s­
stained cytospins from BALF. Cell nuclei are purple to violet, plasma lymphocytes are light blue, monocytes/macrophages are purple, and the granules of eosinophils 
and neutrophils are red­brown and light purple, respectively. (e) PAS­stained lung sections show purple staining of mucus­producing Goblet cells. (F) Cellular 
composition of BALF harvested from WT mice with OVA­induced allergic asthma instilled with OVA­loaded WT pDCs pretreated without or with NGF. (g) IL­4 level in 
BALF described in panel (F). (h) Cytospins stained according to Pappenheim’s method of BALF described in panel (F). (i) PAS­stained lung sections of mice 
described in panel (F) show purple staining of mucus­producing Goblet cells. In panels (D,e,h,i) representative images are shown. Bone marrow­derived WT­pDCs 
and Ex3 pDCs, respectively, are indicated in panels (a,B) as black dots and red squares. In panels (F,g), different treatments of WT pDCs are indicated by black 
dots (no NGF), green dots (0.1 ng ml−1 NGF), and blue dots (100 ng ml−1 NGF). Data in panels (a,B,F,g) are shown as scatterplots on log scale, and the mean 
log­values of one to three independent experiments (one to five animals per group) are indicated by the short horizontal lines (*p < 0.05, **p < 0.01, ***p < 0.005, 
****p < 0.0001).
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ngF alleviates pDc-Mediated 
autoimmune Diabetes in Mice
Based on our observations in the TH2-prone murine model of 
an allergic asthma, we studied influence of pDC-specific activa-
tion of p75NTR on a TH1-prone mouse model of autoimmune 
diabetes. In this RIP-CD80GP model, islet β-cells express the 
neo-self-antigen LCMV-GP and the co-stimulatory molecule 
CD80 under control of rat insulin promotor construct.
After incubation with CpG B and LCMV gp33–41 peptide in 
the absence or presence of NGF, WT pDCs were transplanted 
into heterozygous RIP-CD80GP mice and the development of 
diabetes was determined by consecutive blood glucose measure-
ment. Mice transplanted with NGF-treated WT pDCs displayed 
a delayed increase of blood glucose levels (Figure 3A) and later 
diabetes onset (Figure 3B) compared to mice transplanted with 
WT pDCs without preceding NGF treatment. The median diabe-
tes-free incidence was prolonged by 7.5 days upon pre-treatment 
of transplanted WT pDCs with NGF (with NGF: 37 days; without 
NGF: 29.5 days; p = 0.08; Figure 3B). Two out of 11 (~18%) mice 
transplanted with NGF-treated pDCs developed no diabetes 
within 51 days of observation, while all mice transplanted with 
WT pDCs without preceding NGF treatment developed diabetes 
within 44 days (Figure 3B).
In conclusion, development and progression of antigen-
specific autoimmune diabetes in mice is influenced by degree of 
p75NTR activation on pDC.
p75nTr signaling Modulates  
the activity of human pDcs
To determine whether our findings in mice apply to humans, we 
analyzed the expression of p75NTR by human pDCs. Human 
pDCs express the p75NTR but not the high affinity NGF recep-
tor TrkA (Figure  4A; Figure S2A in Supplementary Material). 
However, levels of p75NTR vary greatly among pDCs harvested 
from individual human donors (Figure 4B).
According to our experiments using murine pDCs, isolated 
primary human pDCs from healthy donors were stimulated ex 
vivo by the TLR9 ligand type A CpG ODN2216 or the negative 
control ODN2243. When human pDCs were incubated with the 
negative control CpG ODN2243 NGF did not show any influ-
ence on IFNα secretion (Figure S2B in Supplementary Material). 
In contrast, increasing doses of NGF diminished the levels of 
IFNα secretion of human pDCs stimulated with ODN2216 in a 
negative, linearly dependent manner (p = 0.00078). The greatest 
significant attenuation occurred in the presence of the high-
est NGF concentration (200  ng  ml−1, p =  0.0006; Figure  4C). 
FigUre 4 | Continued
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FigUre 4 | Continued  
p75 neurotrophin receptor (p75NTR) is expressed by and modulates the activity of human plasmacytoid dendritic cells (pDCs). (a) Expression of p75NTR and TrkA 
receptor by human pDCs (black line) compared with unstained control (filled gray). (B) p75NTR expression by primary human pDCs from three different donors (red, 
green, and blue lines; gray, unstained control). The graph summarizes p75NTR levels (17 donors). (c) IFNα secretion by pDCs (17 donors) stimulated with CpG 
ODN2216 in the presence of nerve growth factor (NGF). (D) IFNα secretion by ODN2216­stimulated pDCs (15 donors) in the presence of NGF and the p75NTR 
inhibitory peptide Pep5. (e) IFNα secretion by pDCs (12 donors), normalized to treatment with ODN2216 alone, and correlated with p75NTR cell­surface expression. 
(F) IFNα secretion by pDCs (17 donors), normalized to treatment with ODN2216 alone, and correlated with BDCA­2 cell­surface expression. (g) IL­6 secretion by 
pDCs (five donors) stimulated overnight with an FcεRIα­specific IgE­crosslinking antibody and incubated with increasing NGF concentrations. (h) IL­6 secretion by 
pDCs (eight donors), normalized to those of antibody treatment only, stimulated overnight with an FcεRIα­specific, IgE­crosslinking antibody in the presence of NGF 
(25 ng ml−1) and the p75NTR inhibitory peptide Pep5. (i) Cell proliferation of CD4+ T cells from four allergic donors cocultured with autologous pDCs in the absence 
or presence of the patient specific antigen and NGF. (J) Level of proinflammatory cytokines in coculture of three allergic donors as described in panel (i). Data in 
panels (D,e,F–h) are shown as scatterplots, and the mean values are indicated by the short horizontal lines. Data in panels (c,i,J) are shown as scatterplots on log 
scale, and the mean log­values are indicated by the short horizontal lines. In panels (a,B), representative images are shown. MFI, mean fluorescent intensity; 
*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001.
11
Bandoła et al. p75NTR and pDCs
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 981
Addition of the p75NTR-specific, inhibitory peptide TAT-Pep5 
to NGF-treated pDCs significantly restored IFNα secretion, 
indicating that the NGF-induced inhibition of the IFN response 
was mediated through p75NTR (p = 0.047; Figure 4D). Further, 
the levels of p75NTR expressed by pDCs correlated with the 
effects of NGF on IFNα secretion in a significant negative and 
linear-dependent manner (p = 0.0028; Figure 4E). Higher levels 
of p75NTR were accompanied by a further decrease in IFNα 
secretion in response to the addition of NGF. Interestingly, also 
the levels of BDCA-2 expressed by pDCs correlated with the 
effects of NGF on IFNα secretion in a significant negative and 
linear-dependent manner (p = 0.0013; Figure 4F). We next stud-
ied the effect of NGF on pDCs treated with an FcεRIα-specific 
IgE-crosslinking antibody. The lowest NGF concentration 
(25 ng ml−1) was the most effective for increasing IL-6 secretion 
(p = 0.0078; Figure 4G). Inhibition of p75NTR using TAT-Pep5 
significantly attenuated the effect of NGF on IL-6 secretion, 
indicating that this effect was specific for p75NTR (p = 0.0059; 
Figure 4H).
To analyze the influence of p75NTR signaling on the capac-
ity of pDCs to stimulate T  cells, we isolated and cocultured 
pDCs and T  cells from allergic patients. In the presence of 
patient-specific allergens, the proliferation of T cells increased 
significantly (p <  0.0001; Figure  4I). Allergen-induced T  cell 
proliferation was significantly further increased by NGF 
(25 ng ml−1, p = 0.0086) in a significant linear-dependent man-
ner (p = 0.0018; Figure 4I). Quantification of cytokines revealed 
that NGF (25 ng ml−1) significantly increased the secretion of 
IL-5 (p = 0.039; Figure 4J).
In conclusion, also human pDC express p75NTR and display 
a ligand-specific alteration in innate and adaptive immune func-
tion of pDC.
ngF Deteriorates gvhD
Human pDCs have been described as a predictive marker for 
the outcome of allogeneic stem cell transplantation and the 
development of GvHD (8, 34). To investigate the role of p75NTR 
signaling in human pDCs in  vivo, we transplanted autologous, 
cocultured pan T cells and pDCs of five different, healthy human 
donors into immunodeficient NSG mice. During coculture cells 
were pre-treated without or with CpG A (0.26  µM) or NGF 
(25 ng ml−1), or both.
Comparing the mean survival rate of NSG mice receiving 
pDCs and T  cells without previous CpG A treatment, no 
significant difference was detectable when cells were cultured 
in absence or presence of NGF (without NGF: 51.6 ±  13.1, 
with NGF: 57.6 ± 17.2 days post transplantation; Figure 5A). 
Mice transplanted with CpG A-treated pDCs and T  cells 
showed a clearly reduced mean survival rate close to statisti-
cal significance when NGF was present during coculture 
(without NGF: 51.0 ±  20.5, with NGF: 35.5 ±  7.8  days post 
transplantation; p =  0.055; Figure  5B). This observed rela-
tion between NGF and CpG A is confirmed by a significantly 
reduced mean survival of NSG mice transplanted with NGF 
and CpG A-treated cells (35.5 ±  7.8  days post transplanta-
tion) compared to mice transplanted with cells treated only 
with NGF (57.6 ± 17.2 days post transplantation; p = 0.015). 
Mice transplanted with cells that received no NGF showed no 
different survival rate independent from CpG A treatment 
(Figures  5C,D). NSG mice transplanted with T  cells only 
displayed no difference in mean survival rate whether they 
were pre-treated without or with NGF.
Analyzing the composition of T cells in the xenograft in more 
detail, a significantly increased proportion of CD4+ T cells was 
observed in the peripheral blood of NSG mice transplanted with 
cocultures of T cells and pDCs treated with both NGF and CpG 
A, compared to CpG A treatment only (p = 0.032; Figure 5E). 
On the other hand, the same coculture conditions resulted 
in a significantly lower number of CD8+ T  cells (p =  0.047; 
Figure 5F). No significant influence of NGF on the proportion 
of CD4+ or CD8+ T  cells in xenograft was detectable when 
transplanted pDCs were not stimulated with CpG A. Changes 
in the number of CD25+ T cells were not observed under the 
studied conditions.
In conclusion, GvHD triggered by pDCs presenting alloan-
tigen and priming alloreactive T  cells is regulated by p75NTR 
activity on pDC thus explaining the janiform role of pDC trans-
plantation approaches described so far.
DiscUssiOn
Plasmacytoid dendritic cells play a pivotal role in the modulation 
of immune responses. Here, we demonstrate, for the first time, 
that both human and murine pDCs express marked amounts of 
FigUre 5 | Nerve growth factor (NGF) aggravates plasmacytoid dendritic cell (pDC)­mediated graft­versus­host reaction in xenotransplantation model. Survival 
curve of NSG mice transplanted with autologous pan T cells and pDCs stimulated without or with NGF in the absence (a) or presence (B) of CpG A. Survival curve 
of NSG mice transplanted with autologous pan T cells and pDCs stimulated without (c) or with (D) NGF in the absence or presence of CpG A. Proportion of human 
CD45+ CD4+ (e) and CD8+ T cells (F) in peripheral blood of NSG mice transplanted with autologous pan T cells and pDCs stimulated without or with NGF in the 
presence of CpG A. In panels (a,B,e,F) data of five experiments each one independent, healthy human donor are indicated by individual horizontal black (without 
NGF treatment) or red (with NGF treatment) lines. Data of five experiments each one independent, healthy human donor are indicated in panels (a,B) by horizontal 
black (without NGF treatment) or red (with NGF treatment) lines, and in panels (c,D) by horizontal black (without CpG A treatment) or green (with CpG A treatment) 
lines, and in panels (e,F) are indicated by individual horizontal black (without NGF treatment) or red (with NGF treatment) lines and measuring points are indicated by 
black (without NGF treatment) or red (with NGF treatment) triangles (*p < 0.05).
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the low affinity neurotrophin receptor p75NTR, but not the high 
affinity neurotrophin receptors TrkA, TrkB, or TrkC (Figures 1A 
and 4A). Therefore, we studied the potential of neurotrophins to 
modulate the function of pDCs in immune responses.
The neurotrophin NGF is implicated in the regulation of 
inflammatory responses. In response to allergen stimulation, 
serum, and BALF from patients with allergic asthma exhibit 
highly increased levels of NGF correlating with the degree of 
airway hyperreactivity (17, 35). Intravenous injection of NGF 
into guinea pigs induces bronchoconstriction in response to 
inhaled histamine (36). Similarly, mice that overexpress NGF 
exhibit severe airway hyperreactivity in response to allergen 
exposure, while the administration of NGF-specific antibodies 
prevents allergen-induced bronchoconstriction (28, 37). 
Mutant Ex3 mice with systemically reduced p75NTR levels 
do not develop asthma in response to allergen challenge (38). 
Initially, the asthma-preventing effects induced by reduced 
p75NTR expression were attributed to cells of the nervous 
system. More recent reports suggest that the failure to develop 
asthma is caused by a reduced p75NTR expression by hemat-
opoietic cells, although the immune effector cells have not been 
identified (39).
Therefore, we investigated the impact of p75NTR signaling in 
pDCs using a modified model of murine OVA-induced allergic 
asthma (29). We sensitized mice through the intratracheal appli-
cation of OVA-loaded pDCs and induced an allergic reaction by 
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subsequent exposure to OVA aerosol. Here, we demonstrate that 
OVA-loaded WT pDCs induce allergic asthma in mice, which 
was present with typical asthma-associated symptoms such as 
Goblet cell hyperplasia, perivascular inflammation, prominent 
eosinophilia, and lung inflammation (Figure  2). Further, the 
preincubation of WT pDCs with NGF strongly enhances the 
symptoms of allergic asthma (Figure 2).
To further investigate the role of p75NTR in pDC-induced 
asthma, we used Ex3 mutant mice. This mouse strain is deficient 
in the full-length transcript of p75NTR, but expresses an alternate 
isoform lacking exon 3 that encodes a receptor unable to bind 
neurotrophins (12). The surface marker profiles of primary pDCs 
derived from spleen and ex vivo differentiated BM-derived pDCs 
from Ex3 and WT mice were identical, indicating no defect in dif-
ferentiation of pDCs in Ex3 mice (Figure 1A). We then applied, 
reciprocally, WT or Ex3 pDCs into each mouse strain, finding 
that the reduced susceptibility of Ex3 mice to developing allergic 
asthma was fully rescued by sensitization with OVA-loaded WT 
pDCs expressing physiological levels of p75NTR (Figure 2). By 
contrast, transplanting OVA-loaded Ex3 pDCs into WT mice 
failed to induce asthmatic reactions. We, therefore, provide 
first and direct evidence that effective sensitization of mice with 
OVA-loaded pDCs depends on functional p75NTR expression 
by pDCs.
Beside their role in the applied allergy model, pDCs have 
been described as a predictive marker for the outcome of allo-
geneic stem cell transplantation and the development of GvHD 
(8, 34). Therefore, we tested whether activation of p75NTR 
modulates the influence of pDCs on GvHD. Transplantation of 
primary human pDCs together with autologous pan T cells led 
to a profound GvHD in NSG mice. When the human xenograft 
was treated with NGF prior to the transplantation these mice 
deceased significantly earlier when transplanted cells were addi-
tionally stimulated by CpG A (Figures 5A,B). Interestingly, we 
observed a shift towards CD4+ T cells penalizing CD8+ T cells 
within the peripheral blood xenograft upon stimulation with 
NGF arguing for a selective T  cell type dependent expansion 
(Figures 5C,D). Comparable alterations of the CD4/CD8 ratio 
have been observed during hematopoietic stem cell transplanta-
tion and development of GvHD both in clinic and mouse models 
(40, 41). But no connection to pDCs, p75NTR, or neurotrophins 
had been suggested.
To further illuminate the role of p75NTR signaling in pDCs, 
we performed in vitro experiments to study the effect of NGF on 
innate and adaptive immune responses. NGF treatment altered 
the production of cytokines in both murine and human pDCs. 
CpG A-induced IFNα production was abrogated by NGF treat-
ment and this effect is specific for p75NTR since the addition 
of the p75NTR-selective, inhibitory TAT-fused peptide Pep5 
to CpG-stimulated and NGF treated human pDCs restored 
the levels of IFNα (Figures  1B and 4C,D) (42). Conversely, 
the addition of NGF increased IL-6 production by WT pDCs 
stimulated with CpG B and human pDCs in response to IgE 
crosslinking (Figures  1B and 4G). This is consistent with 
the findings of Noga et  al., who demonstrated increased IL-6 
secretion by monocyte-derived human DCs in the presence 
of NGF and BDNF (43). Notably, Ex3 mice do not exhibit an 
exacerbated IFNα secretion as would be expected of a recep-
tor mutant lacking the neurotrophin binding site. p75NTR 
signaling is complex and many, in part oppositional, effects 
are mediated by this receptor, e.g., cell survival and apoptosis 
depending on intracellular binding partners (9). There is 
evidence that p75NTR signal transduction does not operate in 
an on–off fashion but different signals seem to be transmitted 
by stimulated and unstimulated receptors, respectively (44). It 
was shown that neurotrophins bind to preformed and cova-
lently linked p75NTR dimers which undergo conformational 
changes in a “scissors-like” manner after NGF binding (45). In 
addition, proteolytic cleavage of p75NTR by α- and γ-secretases 
was proposed as a signaling mechanism (46, 47). Since the Ex3 
strain exhibits expression of a p75NTR isoform we suppose this 
isoform lacking the extracellular neurotrophin binding domain 
behaves as constantly active.
NGF treatment of murine and human pDCs revealed a func-
tional influence of p75NTR signaling on antigen presentation and 
T cell priming (Figures 1E,F). In the presence of NGF-treated 
WT pDCs, CD4+ and CD8+ T  cells showed opposite patterns 
of proliferation and cytokine secretion. This result is also com-
parable to our observations in the GvHD xenotransplantation 
model, which showed a bias toward CD4+ T cell proliferation 
in NSG mice transplanted with NGF-treated human pDCs 
(Figures 5E,F). Furthermore, the addition of NGF to cocultures 
of pDCs and CD4+ T  cells increased the allergen-induced 
proliferation of T  cells and the secretion of IL-5, a key factor 
for growth and eosinophil activation (Figures 4I,J). Since pDCs 
do not express high affinity neurotrophin receptors, the pDC-
induced expansion of T cells and increased IL-5 secretion was 
likely due to regulation by the low affinity neurotrophin recep-
tor p75NTR. Overall, these data indicate that NGF modulates 
cytokine secretion and T cell priming in a p75NTR-dependent 
manner, which has also been reported in human monocyte-
derived dendritic cells and murine BM-derived conventional 
dendritic cells (48, 49).
To define the mechanisms by which p75NTR signaling 
regulates the function of murine pDCs, we analyzed the effects 
of NGF treatment and p75NTR deficiency on the TLR9 signal-
ing pathway. CpG-stimulated murine WT pDCs responded 
with an alleviated TLR9 expression level in response to NGF 
in a concentration-dependent manner (Figure  1B). This was 
not the case for Ex3 pDCs, which generally expressed lower 
levels of TLR9 and IFNα in response to CpG (Figure 1B). TLR9 
activation in pDCs results in the phosphorylation and nuclear 
translocation of transcription factors IRF3 and IRF7, which 
induce IFNα/β expression in response to viral infection and 
DNA sensing (50). We show here that TLR9-mediated phospho-
rylation of IRF3 and IRF7 is altered in cells treated with NGF 
(Figure 1C). More specifically, CpG A-induced phosphorylation 
of IRF3 and IRF7 is diminished by NGF treatment in WT pDCs, 
which provides a possible mechanism for the reduced IFNα pro-
duction observed in NGF-treated pDCs stimulated with CpG 
A (Figures  1B and 4C). In addition, we detected lower levels 
of phosphorylation of IRF3, IKKα/β, and c-Jun in Ex3 pDCs, 
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compared with WT pDCs, whereas the total amounts of these 
proteins were not altered. Using the neural crest-derived cell 
line PC12 Mamidipudi et al. and Wooten et al. demonstrated a 
direct, NGF-induced interaction between p75NTR, IRAK, the 
scaffold protein p62, IKKβ, and TRAF6 that activates NF-κB 
(51, 52). TRAF6, which is a critical factor for the maturation 
and T cell priming capacity of dendritic cells, interacts directly 
with p75NTR and regulates γ-secretase-mediated cleavage of 
p75NTR (47, 53). Notably, TRAF6 binds and activates IRF7 
during TLR-induced IFNα production (54). Interestingly, the 
co-stimulatory molecules differentially expressed by OVA-
stimulated WT and Ex3 pDCs are regulated by members of the 
family of IRF transcription factors (55, 56). It is noteworthy that 
in the absence of exogenously added NGF, WT pDCs expressing 
physiological levels of p75NTR displayed increased activation 
by CpG; higher levels of TLR9 and co-stimulatory molecules; 
increased phosphorylation of IRF3, IRF7, IKKα/β, and c-Jun; 
and a greater ability to stimulate T cells than Ex3 pDCs. These 
observations may be explained by p75NTR activation induced 
by NGF that is produced endogenously or by stimulated T cells, 
suggesting the presence of a p75NTR-dependent feedback loop 
between pDCs and other immune cells (57, 58).
Another promising, connective element of both TLR9 signal-
ing, p75NTR and our observations in the different disease models 
is the small GTPase Rab5, which has been reported to form a 
complex with p75NTR in adipocytes (22). Rab5 plays a role in 
regulating the formation of endosomes, which are essential for 
initiation of TLR9-mediated signaling (59). It is, therefore, pos-
sible that p75NTR signaling regulates pDCs function by interact-
ing with various molecules of the TLR9 signaling pathway.
TLR9 signaling contributes to various disease states, including 
the onset of autoimmune diabetes. In the NOD mouse, application 
of a TLR9 antagonist or depletion of type 1 IFN producing pDCs 
resulted in inhibition of diabetogenic CD8+ T cells and delayed 
diabetes onset (60, 61). Comparably, in an adapted murine 
model of autoimmune diabetes, we have shown that a transfer of 
antigen-loaded and CpG-stimulated pDCs treated with NGF led 
to an alleviated clinical phenotype in heterozygous RIP-CD80GP 
mice characterized by reduced glucose levels and delayed onset 
of diabetes compared with pDCs stimulated with CpG alone 
(Figure 3) (26). This aligns with the finding that NGF treatment 
of CpG-stimulated pDCs in vitro results in reduced expression 
of TLR9 and significantly lowers the level of IFNα. Collectively, 
our data suggest that p75NTR signaling plays a dual role in the 
regulation of pDCs function, since activation of this pathway 
abrogates pDCs functions that contribute to autoimmunity, but 
also promotes pDCs functions that enhance immune responses 
in models of OVA-induced asthma and transplantation-induced 
GvHD.
In conclusion, we found that pDCs express the low affinity 
neurotrophin receptor p75NTR and demonstrated that its expres-
sion reflects a basic phenotypic feature of pDCs. p75NTR medi-
ates NGF-driven regulation of pDC-directed immune responses, 
including cytokine production and T  cell priming. The results 
of functional experiments suggest that p75NTR-NGF signaling 
influences activation of IRF3, IRF7, c-Jun, and IKKα/β, revealing 
a novel regulatory circuit in pDC-mediated immune responses. 
Our central finding of functional expression of p75NTR by pDCs 
provides a promising target for future therapeutic interventions 
in allergic diseases, inflammatory disorders, and autoimmune 
diseases.
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